temozolomide has been researched along with Hematologic Neoplasms in 5 studies
Hematologic Neoplasms: Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The alkylating agent temozolomide (TMZ) is widely used for the treatment of gliomas." | 9.17 | Secondary hematological malignancies associated with temozolomide in patients with glioma. ( Miyakita, Y; Momota, H; Narita, Y; Shibui, S, 2013) |
| "Temozolomide (TMZ) is widely used in high-grade glioma (HGG)." | 7.85 | Haematological malignancies following temozolomide treatment for paediatric high-grade glioma. ( Beilken, A; Corbacioglu, S; Dilloo, D; Driever, PH; Dürken, M; Gielen, GH; Hoffmann, M; Karremann, M; Krämer, N; Kramm, CM; Kulozik, A; Scheurlen, W; von Bueren, AO; Wiese, M, 2017) |
| "The alkylating agent temozolomide (TMZ) is widely used for the treatment of gliomas." | 5.17 | Secondary hematological malignancies associated with temozolomide in patients with glioma. ( Miyakita, Y; Momota, H; Narita, Y; Shibui, S, 2013) |
| "Temozolomide (TMZ) is widely used in high-grade glioma (HGG)." | 3.85 | Haematological malignancies following temozolomide treatment for paediatric high-grade glioma. ( Beilken, A; Corbacioglu, S; Dilloo, D; Driever, PH; Dürken, M; Gielen, GH; Hoffmann, M; Karremann, M; Krämer, N; Kramm, CM; Kulozik, A; Scheurlen, W; von Bueren, AO; Wiese, M, 2017) |
| "Temozolomide (TZM) is a DNA-methylating agent that has recently been introduced into various clinical trials for treatment of solid or hematologic neoplasias, including brain lymphomas." | 1.31 | Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site. ( Bonmassar, E; d'Amati, G; Graziani, G; Leonetti, C; Portarena, I; Scarsella, M; Tentori, L; Zupi, G, 2002) |
| "Temozolomide was studied using a continuous exposure at final concentrations from 0." | 1.30 | Activity of temozolomide against human tumor colony-forming units. ( Dugan, M; Gerson, SL; Izbicka, E; Raymond, E; Soda, H; Von Hoff, DD, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Karremann, M | 1 |
| Krämer, N | 1 |
| Hoffmann, M | 1 |
| Wiese, M | 1 |
| Beilken, A | 1 |
| Corbacioglu, S | 1 |
| Dilloo, D | 1 |
| Driever, PH | 1 |
| Scheurlen, W | 1 |
| Kulozik, A | 1 |
| Gielen, GH | 1 |
| von Bueren, AO | 1 |
| Dürken, M | 1 |
| Kramm, CM | 1 |
| Momota, H | 1 |
| Narita, Y | 1 |
| Miyakita, Y | 1 |
| Shibui, S | 1 |
| Tear, S | 1 |
| Raymond, E | 1 |
| Izbicka, E | 1 |
| Soda, H | 1 |
| Gerson, SL | 1 |
| Dugan, M | 1 |
| Von Hoff, DD | 1 |
| Tentori, L | 1 |
| Leonetti, C | 1 |
| Scarsella, M | 1 |
| d'Amati, G | 1 |
| Portarena, I | 1 |
| Zupi, G | 1 |
| Bonmassar, E | 1 |
| Graziani, G | 1 |
1 trial available for temozolomide and Hematologic Neoplasms
| Article | Year |
|---|---|
Secondary hematological malignancies associated with temozolomide in patients with glioma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chil | 2013 |
4 other studies available for temozolomide and Hematologic Neoplasms
| Article | Year |
|---|---|
Haematological malignancies following temozolomide treatment for paediatric high-grade glioma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Austria; Child; Child, Preschool; Dacarbazine; Female | 2017 |
American Society of Hematology--48th Annual Meeting and Exposition. Therapeutic approaches for hematological cancers. 9-12 December 2006 Orlando, FL, USA.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Clinical Trials, Phase I as Topic | 2007 |
Activity of temozolomide against human tumor colony-forming units.
Topics: Adrenal Gland Neoplasms; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; | 1997 |
Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Dacarbazi | 2002 |